CA2443437A1 - Antibodies specific for cd44v6 - Google Patents

Antibodies specific for cd44v6 Download PDF

Info

Publication number
CA2443437A1
CA2443437A1 CA002443437A CA2443437A CA2443437A1 CA 2443437 A1 CA2443437 A1 CA 2443437A1 CA 002443437 A CA002443437 A CA 002443437A CA 2443437 A CA2443437 A CA 2443437A CA 2443437 A1 CA2443437 A1 CA 2443437A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
antibody
nucleic acid
biwa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002443437A
Other languages
English (en)
French (fr)
Inventor
Guenther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Karl-Heinz Heider
John J. Miglietta
Augustinus Antonius Maria Silvester Van Dongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2443437A1 publication Critical patent/CA2443437A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA002443437A 2001-05-18 2002-05-17 Antibodies specific for cd44v6 Abandoned CA2443437A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
EP01112237.1 2001-05-18
US32514701P 2001-09-26 2001-09-26
US60/325,147 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (1)

Publication Number Publication Date
CA2443437A1 true CA2443437A1 (en) 2002-11-28

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002443437A Abandoned CA2443437A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Country Status (18)

Country Link
EP (1) EP1397387A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005504517A (cg-RX-API-DMAC7.html)
CN (1) CN1541226A (cg-RX-API-DMAC7.html)
AR (1) AR036154A1 (cg-RX-API-DMAC7.html)
BR (1) BR0210905A (cg-RX-API-DMAC7.html)
CA (1) CA2443437A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033476A3 (cg-RX-API-DMAC7.html)
EA (1) EA200301169A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034838A (cg-RX-API-DMAC7.html)
EE (1) EE200300569A (cg-RX-API-DMAC7.html)
HU (1) HUP0400030A3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010523A (cg-RX-API-DMAC7.html)
PE (1) PE20021098A1 (cg-RX-API-DMAC7.html)
PL (1) PL365735A1 (cg-RX-API-DMAC7.html)
SK (1) SK15592003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002094879A1 (cg-RX-API-DMAC7.html)
YU (1) YU91403A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307365B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187591A1 (en) * 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
ES2681195T3 (es) * 2007-06-13 2018-09-12 Zymogenetics, Inc Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
SI2531527T1 (sl) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP7859981B2 (ja) * 2020-03-06 2026-05-15 ジーオー セラピューティクス,インコーポレイテッド 抗グリコcd44抗体およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
CA2149635A1 (en) * 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187591A1 (en) * 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Also Published As

Publication number Publication date
SK15592003A3 (sk) 2004-06-08
CN1541226A (zh) 2004-10-27
HUP0400030A2 (hu) 2004-04-28
EP1397387A1 (en) 2004-03-17
EE200300569A (et) 2004-04-15
ECSP034838A (es) 2003-12-24
WO2002094879A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
CZ20033476A3 (cs) 2004-05-12
AR036154A1 (es) 2004-08-18
YU91403A (sh) 2006-05-25
PE20021098A1 (es) 2003-02-11
BR0210905A (pt) 2004-06-08
EA200301169A1 (ru) 2004-06-24
MXPA03010523A (es) 2004-07-01
ZA200307365B (en) 2004-05-10
JP2005504517A (ja) 2005-02-17
PL365735A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
AU2022200108B2 (en) Chimeric receptors to FLT3 and methods of use thereof
US7417127B2 (en) Antibodies specific for CD44v6
KR102779944B1 (ko) 키메라 수용체 및 그의 사용 방법
JP2025061674A (ja) 前立腺特異的膜抗原carおよびその使用方法
KR102427334B1 (ko) 키메라 항원 및 t 세포 수용체 및 사용 방법
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
SK15592003A3 (sk) Protilátková molekula, farmaceutický prostriedok s jej obsahom a jej použitie
BG62386B1 (bg) Метод за лечение на в-клетъчна лимфома
CN109475541A (zh) 用于治疗非erk mapk通路抑制剂抗性癌症的方法和组合物
CA2831111A1 (en) Cd37-binding molecules and immunoconjugates thereof
Braun et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
CN118234744A (zh) 靶向hla-g阳性癌症的嵌合抗原受体
US5663481A (en) Animal model of the human immune system
KR20240007911A (ko) Cd5-양성 암을 표적화하기 위한 키메라 항원 수용체
EP3941494A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
CN118251227A (zh) 负载抗体的免疫细胞及用于癌症治疗的方法
WO2022020720A9 (en) Compositions and methods for treating cancer
US6933150B1 (en) Relationship of ABC transport proteins with hematopoietic stem cells and methods of use thereof
Jin et al. Simultaneous administration of a low‐dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long‐term survival of cardiac allograft in rats
Schneider et al. A self-immunomodulating myoblast cell line for erythropoietin delivery
WO2023020472A1 (en) Mesothelin-targetting antibodies and uses thereof in cancer therapies
JPH11514884A (ja) 腫瘍にあるサイクリンg1の発現
CA2286860A1 (en) Radioisotope concentrator methods and compositions
HK1070079A (en) Antibodies specific for cd44v6
AU2002310823A1 (en) Antibodies specific for CD44v6

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued